If your GLP-1 is helping you reach your health goals but your GI symptoms are getting in the way, you dont have to choose between the two
Riluzole was the first FDA-approved compound for ALS (in 1995), which inhibits glutamatergic neurotransmission and thus inhibits excitotoxicity (Dharmadasa and Kiernan, 2018
These results are averages individual responses vary significantly based on metabolic starting point, adherence, protein intake, and exercise
Their superior specificity in targeting interactions, tunable half-lives, and typically lower toxicity and immunogenicity give peptides advantages over other modalities
This guide provides evidence-based information aligned with UK clinical guidance
Most cases are mild to moderate